Sierra Oncology Reports 2020 Year End Results
News provided by
Share this article
Share this article
– MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 –
– Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various
Patient Subsets and Dosing Durability –
– Key Appointments Made to Executive Team in Preparation for Commercial Execution –
SAN MATEO, Calif., March 11, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operational results for the fourth quarter and fiscal year ended December 31, 2020.
News Category Global Banking & Finance Reviews
Loop Insights Signs LOI To Acquire Passcreator, A Leading European Digital Wallet And Mobile Marketing Company With Tier-1 Global Clients
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES./
VANCOUVER, British Columbia, Jan. 12, 2021 Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space, is pleased to announce the signing of a Letter Of Intent (“LOI”) to acquire Passcreator, a leading European digital wallet and mobile marketing company with Tier-1 clients such as Mercedes-Benz and BMW. The acquisition is expected to be completed by late January or early February 2021, subject to customary due diligence and Exchange approvals.